Publications by authors named "M Zalacain"
Article Synopsis
- Pediatric high-grade gliomas (pHGGs), particularly diffuse midline gliomas (DMGs), are highly aggressive tumors with low survival rates, yet the combination of Delta-24-RGD and ONC201 has shown potential for enhanced treatment efficacy.
- In laboratory and mouse model studies, the combination treatment did not alter virus replication but demonstrated a synergistic or additive cytotoxic effect, leading to increased DNA damage and metabolic disruptions in tumor cells.
- Additionally, the combination treatment improved survival rates in mice models and led to a shift in the tumor microenvironment towards a more proinflammatory state, indicating a stronger immune response against the tumors.
Article Synopsis
- - ANT3310 is a new drug being tested alongside meropenem (MEM) to treat serious infections caused by drug-resistant bacteria, specifically carbapenem-resistant Gram-negative pathogens.
- - In tests with 905 clinical bacterial isolates, the combination of MEM and ANT3310 showed significantly better antibacterial activity, reducing MIC values for carbapenem-resistant Enterobacterales from over 32 µg/mL to much lower levels.
- - The combination of MEM and ANT3310 effectively inhibited the growth of nearly all tested resistant strains and proved effective in mouse models of thigh and lung infections, showing promise as a treatment option compared to other existing drug combinations.
Article Synopsis
- Diffuse intrinsic pontine glioma (DIPG) is a serious brain tumor and is the most common cause of cancer deaths in kids.
- Scientists found that a protein called TIM-3 is present in both the tumor cells and nearby cells, which may help the tumor grow.
- By blocking TIM-3, they noticed that it helped some mice live longer and fight off the tumor, showing it could be a good target for new treatments for DIPG.
Pseudomonas aeruginosa is a common pathogen in cystic fibrosis (CF) patients and a major contributor to progressive lung damage. P. aeruginosa elastase (LasB), a key virulence factor, has been identified as a potential target for anti-virulence therapy.
View Article and Find Full Text PDFLasB elastase is a broad-spectrum exoprotease and a key virulence factor of , a major pathogen causing lung damage and inflammation in acute and chronic respiratory infections. Here, we describe the chemical optimization of specific LasB inhibitors with druglike properties and investigate their impact in cellular and animal models of infection. Competitive inhibition of LasB was demonstrated through structural and kinetic studies.
View Article and Find Full Text PDF